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Abstract 
Aims: Hepatocellular carcinoma (HCC) is the third leading cause of cancer mortality worldwide. Many microRNAs 
(miRNAs), small non‑coding RNAs, are involved in regulating cancer cell proliferation, metastasis, migration, invasion 
and apoptosis.
Main methods: We investigated the expression of miR‑135a in HCC cell lines and clinical tissues. The effect of miR‑
135a on migration and invasion of HepG2 and MHCC‑97L were examined using wound healing and Transwell assay. 
We determined the expression of miR‑135a, forkhead box O1 (FOXO1), matrix metalloproteinase‑2 (MMP‑2) and Snail 
using real‑time PCR and western blotting.
Key findings: We found miR‑135a was upregulated in HCC cell lines and tissues. miR‑135a overexpression promoted 
HCC cells migration and invasion, whereas miR‑135a inhibition suppressed HCC cells migration and invasion. miR‑
135a overexpression could upregulate the expression of MMP2, Snail and the phosphorylation of AKT, but decreased 
FOXO3a phosporylation. Tumor suppressor FOXO1 was the direct target for miR‑135a.
Significance: Our results suggested that miR‑135a might play an important role in promoting migration and inva‑
sion in HCC and presents a novel mechanism of miRNA‑mediated direct suppression of FOXO1 in HCC cells.
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Background
Hepatocellular carcinoma (HCC) is the fifth most com-
mon cancer and the third leading cause of cancer-related 
mortality worldwide [1, 2]. As most HCC patients in 
China are infected with hepatitis B virus (HBV) and 
hepatitis C virus (HCV), the incidence and mortality are 
higher. Chinese cases account for 55 % of all HCC cases 
globally [1]. Currently, the most effective therapy is sur-
gery. Nevertheless, about 85  % of patients have locally 
advanced tumor or distant metastasis at diagnosis, and 
are not suitable candidates for surgery. Consequently, 
they cannot be cured by surgical resection and liver 
transplantation, which renders curing HCC difficult [3]. 
Therefore, there is an urgent need for in-depth under-
standing of the molecular mechanisms of HCC metasta-
sis to identify new treatment targets.
microRNAs (miRNAs), small non-coding RNA con-
taining 17–27 nucleotides, regulate gene expression by 
mediating target mRNA degradation or translational 
repression. Recently, it was revealed that many miR-
NAs play crucial roles in tumorigenesis and cancer pro-
gression [4, 5]. Most miRNAs are involved in regulating 
cancer cell proliferation, migration, invasion, metastasis 
and apoptosis. miR-135a plays important role in many 
tumors. In ovarian cancer, miR-135a acts as a tumor sup-
pressor by downregulating homeobox A10 (HOXA10) 
expression with concomitant enhancement of caspase-3 
and p53, and reduction of Bcl-2 [6, 7]. In breast cancer, 
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miR-135a promotes tumor migration and invasion by 
targeting HOXA10 [8]. In classic Hodgkin lymphoma, 
miR-135a mediates Janus kinase 2 (JAK2) downregula-
tion and decreases both the mRNA and protein levels 
of the anti-apoptotic gene Bcl-xL (BCL2L1), leading to 
apoptosis [9]. In HCC, miR-135a transcribed by forkhead 
box (FOX) M1 induces the development of portal vein 
tumor thrombus by promoting metastasis, and inhibiting 
metastasis suppressor 1 (MTSS1) [10]. However, what 
is/are the target gene(s) of miR-135a and how miR-135a 
causes metastasis in HCC remain poorly understand.
FOXO1 which is a member of the forkhead transcrip-
tional factor family, functions as a tumor suppressor in 
various carcinomas. For example, breast, prostate, cervi-
cal, gastric and endometrial cancer, its downregulation 
accelerates tumor progression in these tumors [11–15]. 
FOXO1 expression also is downregulated in HCC [16]. 
Xu et al. [17] find that FOXO1 and FOXO3a expression 
are upregulated when oncomiRNA miR-96 is inhibited in 
HCC cells, inhibition of FOXO1 and FOXO3a promoted 
HCC cell proliferation and colony formation ability. 
However, the function of miR-135a on HCC metastasis 
has not been reported.
In the current study, we determined miR-135a expres-
sion in HCC cells, normal liver cells, HCC tissues and 
adjacent normal live tissues and investigated the effect 
of miR-135a overexpression on HCC cell migration 
and invasion. miR-135a likely induced HCC cell metas-
tasis and invasion by directly targeting the 3′ untrans-
lated region (3′ UTR) of FOXO1 mRNA, consequently 
increasing Snail and matrix metalloproteinase-2 (MMP2) 
expression, inhibiting FOXO3a phosphorylation, and 
promoting AKT phosphorylation. Our results suggest 
that miR-135a may play an important role in the develop-
ment and progression of HCC.
Methods
Cell culture and transfection
Human HCC cell lines Bel-7402, Huh7, HepG2, MHCC-
97H, MHCC-97L and SMMC-7721 and the immortal-
ized normal liver epithelial cell LO2 were obtained from 
ATTC. HCC cells was maintained in Dulbecco’s modified 
Eagle’s medium (Invitrogen, Carlsbad, CA, USA) sup-
plemented with 10 % fetal bovine serum (FBS; HyClone, 
Logan, UT, USA). LO2 cells were cultured in bronchial 
epithelial growth medium (Clonetics Corporation, Walk-
ersville, MD, USA), supplemented with 5 ng/ml epithelial 
growth factor, 70 ng/ml phosphoethanolamine, and 10 % 
FBS. Cells were maintained in a humidified atmosphere 
at 37 °C with 5 % CO2.
miR-135a mimic, miR-135a inhibitor, and their nega-
tive control were purchased from RiboBio Co (Guang-
zhou, Guangdong, China). 20 nm olignonucleotides were 
transfected into cells using Lipofectamine RNAiMAX 
according to the manufacturer’s instruction.
Wound healing assay
One day before the wound healing assay was performed, 
stable HepG2 and MHCC-97L cells were trypsinized and 
seeded equally in 6-well cell culture plates, and grew to 
almost total confluence in 24 h. We created an artificial 
homogenous wound in the monolayer using a sterile 100-
μl pipette tip. After scratching, the cells were washed 
with serum-free medium. Images of cells migrating into 
the wound were captured at 0 and 24 h using an inverted 
microscope (40×).
In vitro invasion assay
We performed the invasion assay using Transwell cham-
bers containing Matrigel-coated 8-μm membrane filter 
inserts. Cells were trypsinized and suspended in serum-
free medium. Then, 1.5  ×  105 cells were added to the 
top chamber, whereas the bottom chamber was filled 
with medium containing 10  % FBS. After 48-h incuba-
tion, cells that had invaded through the membrane to 
the lower surface were fixed with 4 % paraformaldehyde, 
stained with hematoxylin, and counted under  ×100 
magnification.
RNA extraction and real‑time quantitative PCR
Total RNA from human HCC cell lines (Bel-7402, 
Huh7, HepG2, MHCC-97H, MHCC-97L, SMMC-7721) 
and primary tumor tissues was extracted using TRIzol 
according to the manufacturer’s instructions (Invitro-
gen). The extracted RNA was dissolved with RNase-free 
water pretreated with diethyl phosphorocyanidate. Com-
plementary DNA was synthesized from total RNA using 
reverse transcription–PCR (RT-PCR) with specific prim-
ers. Expression data were normalized to the geometric 
mean of the housekeeping gene glyceraldehyde-3-phos-
phate dehydrogenase (GAPDH) to control the variability 
of expression. miRNA expression was defined based on 
the threshold cycle (Ct), and relative expression levels 
were calculated as 2−[(Ct of miR−135a) − Ct of U6] after normali-
zation with reference to U6 small nuclear RNA expres-
sion. The primers for RT-PCR and real-time PCR were 
designed using Primer Express Software V2.0 (Applied 
Biosystems, Foster City, CA, USA).
Western blotting
Equal amounts of protein were separated by electropho-
resis on a 10  % sodium dodecyl sulfate–polyacrylamide 
gel and electrotransferred to a nitrocellulose mem-
brane. After blocking with 5  % non-fat milk solution in 
Tris-buffered saline with Tween20 (TBST) for 1  h, the 
membrane was incubated with primary antibodies for 
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FOXO3a, phosphorylated (p)-FOXO3a, AKT, p-AKT, 
MMP2, and Snail for 1.5–2 h at room temperature. Anti–
β-actin antibody was used as the internal loading control.
Luciferase assay
Cells (5 × 105) were seeded in triplicate in 6-well plates 
and allowed to settle for 24 h. Luciferase plasmid pGL3-
FOXO-3′UTR (wild-type/mutant, wt/mu) or control 
luciferase plasmid plus 1  ng pRL-TK Renilla plasmid 
(Promega, Madison, WI, USA) were transfected into 
HepG2 cells using Lipofectamine 2000 according to the 
manufacturer’s recommendation (Invitrogen). Luciferase 
and Renilla signals were measured 48 h after transfection 
using a Dual Luciferase Reporter Assay Kit according to 
the manufacturer’s protocol (Promega). Three independ-
ent experiments were performed and the data are pre-
sented as the mean ± SD.
Statistical analysis
Statistical analysis was performed using SPSS 13.0 statis-
tical software package, Student t test was used to evalu-
ate significant differences between two groups of data in 
all pertinent experiments. p < 0.05 (2-tailed paired t-test) 
was considered significantly different for two groups of 
data.
Results
miR‑135a was upregulated in HCC cell lines and tissues
Real-time quantitative PCR assay revealed that miR-135a 
was significantly upregulated in the six HCC cell lines 
(Bel-7402, Huh7, HepG2, MHCC-97H, MHCC-97L and 
SMMC-7721) compared with that of in normal LO2 liver 
cells (Fig.  1a). We further analyzed miR-135a expres-
sion in HCC tissues (T) and adjacent normal liver tissues 
(ANT), suggesting miR-135a was upregualted in HCC 
tissues compared to adjacent normal live tissues (Fig. 1b). 
These suggested that miR-135a was upregulated in hepa-
tocellular carcinoma, it might be an oncomiRNA.
miR‑135a regulates HCC cell migration and invasion
To investigate the biological role of miR-135a in the 
development and progression of HCC, we transfected 
miR-135a mimic or control into HepG2 and MHCC-97L 
to determine its effect on cellular migration and inva-
sion. miR-135a overexpression dramatically increased 
the HCC cell migration compared with that of in nega-
tive control (NC)-transfected cells. When miR-135a was 
inhibited, the HCC cell migration was decreased com-
pared to that of in NC (NC-in) group (Fig. 2a and Addi-
tional file  1: Figure  S1A). The Transwell invasion assay 
revealed that miR-135a overexpression promoted HCC 
cell invasion, Inhibition of miR-135a suppressed HCC 
cell invasion (Fig.  2b and Additional file  1: Figure  S1B). 
Therefore, overexpression of miR-135a promoted HCC 
cell migration and invasion, inhibition of miR-135a sup-
pressed HCC cell migration and invasion.
miR‑135a regulates metastasis‑associated genes 
expression
Activation PI3  K/AKT pathway plays critical role in 
tumor metastasis [18], FOXO3a activation leads to trans-
activation of the E-cadherin expression and inhibit EMT 
associated genes expression. Phosphorylation of FOXO3a 
induces its nuclear export, and promotes FOXO3a deg-
radation [19]. Snail and MMP2 promote tumor invasion 
and metastasis. Western blotting analysis revealed that 
miR-135a upregulation inhibited FOXO3a phosphoryla-
tion and increased AKT phosphorylation and MMP2 
Fig. 1 miR‑135a is upregulated in HCC cells and tissues. a Real‑time PCR analysis of miR‑135a expression in normal liver cells (LO2) and HCC cell 
lines Bel‑7402, Huh7, HepG2, MHCC‑97H, MHCC‑97L, and SMMC‑7721. b miR‑135a expression in eight paired HCC tissues (T) and their adjacent 
normal tissues (ANT). Average miR‑135a expression was normalized to U6 expression. Bars represent the mean of three independent experiments. 
*p < 0.05
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and Snail expression, knockdown of miR-135a promoted 
the phosphorylation of FOXO3a and inhibited AKT 
phosphorylation and the expression of MMP2 and Snail 
(Fig.  3a and Additional file  2: Figure  S2A). Luciferase 
analysis revealed that miR-135a upregulation promoted 
the transcription of the metastasis-associated genes 
MMP2 and Snail, vice verse (Fig. 3b and Additional file 2: 
Figure S2B).
miR‑135a directly targeted FOXO1 in HCC cells
We used TargetScan, PicTar and miRBase to predict the 
target genes of miR-135a, and found that FOXO1 was one 
of the candidates, the potential binding sequence for miR-
135a was identified in the 3′UTR of FOXO1 (Fig. 4a). We 
also observed a consistent and dose-dependent reduc-
tion of luciferase activity upon miR-135a transfection 
in HepG2 cells (Fig.  4b). As predicted, ectopic expres-
sion of miR-135a in the HepG2 cells decreased FOXO1 
expression, while miR-135a-in transfection increased its 
expression (Fig. 4c). We also determined FOXO1 expres-
sion in normal LO2 liver cells and HCC cells, real-time 
quantitative PCR assay found the mRNA level of FOXO1 
in LO2 was the same as HCC cells (Additional file 3: Fig-
ure S3), but FOXO1 was downregulated in protein level 
in HCC cells (Additional file  4: Figure  S4C), suggesting 
miR-135a inhibited the translation of FOXO1. We also 
determined the role of miR-35a in LO2 cells, and found 
knockdown of LO2 slightly inhibited the migration and 
invasion of cells (Additional file 4: Figure S4A, B).
Discussion
In the present study, miR-135a expression was upregu-
lated in HCC cells and HCC tissue. Our findings indi-
cate that ectopic expression of miR-135a enhanced HCC 
cell migration and invasion, while miR-135a inhibition 
reduced these effects. Moreover, we proved that miR-
135a upregulation in HCC cells led to overexpression of 
the metastasis-associated genes MMP2 and SNAI1, and 
the phosphorylation of AKT, and increased FOXO3a 
phosphorylation. The luciferase assay indicated that 
miR-135a downregulates FOXO1 by targeting its 3′ 
UTR directly. These findings suggested that miR-135a 
Fig. 2 Ectopic expression of miR‑135a promoted HCC cell metastasis and increased adhesion. a Wound healing determined the effect of miR‑135a 
on cell migration by modulating miR‑135a expression. b Transwell invasion assay determined the effect of miR‑135a on cell invasion by modulating 
miR‑135a expression. Error bars represent mean ± SD of three independent experiment
Page 5 of 7Zeng et al. Cancer Cell Int  (2016) 16:63 
upregulation might play an important role in promoting 
carcinogenesis and progression of HCC.
FOXO1 is a famous tumor suppressor gene, and regulates 
cell proliferation, invasion, metastasis and apoptosis. For 
example, Lee et al. [20] reported that inhibition of Aurora 
A by RNA interference in HCC cells upregulated FOXO1 
in a p53-dependent manner, which induces cell cycle arrest. 
Wang et  al. [21] demonstrated that miR-145 suppresses 
HCC by downregulating insulin receptor substrate-1 (IRS1) 
and inhibiting the downstream AKT/FOXO1 signaling.
Fig. 3 miR‑135a induced migration and invasion by increasing the expression metastasis‑associated genes. a Western blots of FOXO3a, p‑FOXO3a, 
AKT, p‑AKT, MMP2 and Snail in HepG2 cells transfected with miR‑135a mimic or miR‑135a inhibitor. β‑actin was used as the loading control. b Real‑
time PCR analysis of MMP2 and Snail expression in HepG2 cells. Error bars represent mean ± SD of three independent experiment. *p < 0.05
Fig. 4 miR‑135a downregulated FOXO1 by directly targeting the FOXO1 3′ UTR. a Predicted miR‑135a target sequences in 3′ UTR of FOXO1 
(FOXO1‑3′UTR) and mutant containing three mutated nucleotides (in green) in FOXO1‑3′UTR (FOXO1‑3′UTR‑mut). b Luciferase assays of HepG2 
cells transfected with pGL3 control, pGL3‑FOXO1‑3′UTR, or pGL3‑FOXO1‑3′UTR‑mut reporter and 20 nM or 50 nM miR‑135a mimic. c Western blot 
of FOXO1 expression after miR‑135a overexpression or knockdown on HepG2. Error bars represent mean ± SD of three independent experiments. 
*p < 0.05
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FOXO1 also plays a role in metastasis and invasion in T 
lymphocyte cancer, rhabdomyosarcoma, ovarian cancer, 
breast cancer, and prostate cancer. FOXO1 targeting of 
family with sequence similarity 65 member B (Fam65b) 
tonically dampens chemokine-induced migration by 
repressing Ras homolog family member A (RhoA) activ-
ity in T lymphocytes [22]. In breast cancer, cell division 
cycle 25A (CDC25A) mediates metastasis by regulating 
MMP1 through FOXO1 [23]. In prostate cancer, FOXO1 
inactivation due to frequent loss of phosphatase and ten-
sin homolog (PTEN) in prostate cancer cells may render 
the oncogenic activities of runt-related transcription fac-
tor 2 (Runx2) unchecked, thereby driving promiscuous 
expression of Runx2 target genes involved in cell migra-
tion and invasion and favoring prostate cancer progres-
sion [24]. Recently, Wilson K.C. Leung and colleagues 
found Wnt/β-Catenin can activate miR-183/96/182 to 
inhibit FOXO1 to promote the invasion and metastasis of 
HCC [25], this suggesting FOXO1 inhibits HCC invasion 
and metastasis.
In this study, we demonstrated that FOXO1 is also an 
miR-135a target that promotes HCC metastasis and pre-
sents a novel mechanism of miRNA-mediated FOXO1 
downregulation. Bioinformatics analysis indicated that 
the tumor suppressor FOXO1 is a theoretical target gene 
of miR-135a. The wound healing and Transwell assays 
showed that miR-135a overexpression promoted HCC 
cell migration and invasion. Western blotting and real-
time PCR revealed that metastasis-related genes were 
upregulated in HCC cells transfected with miR-135a 
mimic, while miR-135a inhibition decreased the expres-
sion of the metastasis-related genes. The luciferase activ-
ity assay and point mutation analysis demonstrated that 
miR-135a mediated FOXO1 downregulation by binding 
to the FOXO1 3′ UTR. This suggested that the biologi-
cal function of miR-135a was against FOXO1 to inhibit 
HCC cell migration and invasion. Nevertheless, one limi-
tation in this study was that we were unable to clarify the 
particular mechanism of miR-135a facilitation of HCC 
metastasis and the related signaling pathway. Therefore, 
further research was required to explore the biological 
function of miR-135a.
Conclusion
miR-135a is an oncogenic miRNA in HCC and promotes 
HCC cell migration and invasion, which plays a role in 
HCC progression. Complete understanding of its biologi-
cal function will aid in the discovery of a novel therapeu-
tic target for treating HCC.
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miR‑135a expression. B. Transwell invasion assay determined the effect of 
miR‑135a on cell invasion by modulating miR‑135a expression. Error bars 
represent mean ± SD of three independent experiment.
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analysis of FOXO3a, p‑FOXO3a, AKT, p‑AKT, MMP2 and Snail in MHCC‑97L 
cells transfected with miR‑135a mimic or miR‑135a inhibitor. β‑actin was 
used as the loading control. B. Real‑time PCR analysis of MMP2 and Snail 
expression in MHCC‑97L cells. Error bars represent mean ± SD of three 
independent experiment. *p < 0.05.
Additional file 3: Figure S3. Real‑time PCR determined FOXO1 expres‑
sion in normal live cells and HCC cells.
Additional file 4: Figure S4. The effect of miR‑135a on migration and 
invasion of LO2. A. A. Wound healing determined the effect of miR‑135a 
on migration of LO2 by inhibiting miR‑135a expression. B. Transwell inva‑
sion assay determined the effect of miR‑135a on invasion of LO2 by inhib‑
iting miR‑135a expression. C. Western blot determined FOXO1 expression 
in LO2 cells, HepG2 cells and HepG2 cells transfected miR‑135a inhibitor. 
β‑actin was used as the loading control. Error bars represent mean ± SD 
of three independent experiment.
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